CD79A and COVID-19: We recently demonstrated that intramuscularly administered COVID-19 vaccines fail to induce mucosa-residing IgA against several SARS-CoV-2 variants in patients with chronic liver disease and in the same IBD cohort assessed in the present study [31,37].